Nomikos, N., Naoum, P., Athanasakis, Kostas and Kyriopoulos, I 
ORCID: 0000-0002-3932-8228
(2024)
Cost-effectiveness analysis of filgotinib as a first-line treatment for biologic-naive patients with Ulcerative Colitis in Greece.
Value in Health, 27 (12, Supplement).
S80 - S80.
ISSN 1098-3015
Identification Number: 10.1016/j.jval.2024.10.419
Abstract
The aim of this study was to evaluate the cost-effectiveness of introducing filgotinib as a treatment option for patients with moderate to severe Ulcerative Colitis(UC) who are biologic-naïve in Greece compared to adalimumab, golimumab and vedolizumab.
| Item Type: | Article |
|---|---|
| Divisions: | Health Policy |
| Subjects: | R Medicine > RA Public aspects of medicine R Medicine > RM Therapeutics. Pharmacology |
| Date Deposited: | 11 Mar 2025 08:36 |
| Last Modified: | 11 Mar 2025 08:57 |
| URI: | http://eprints.lse.ac.uk/id/eprint/127534 |
Actions (login required)
 |
View Item |
